This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The heart and vascular medication market continues to be a critical focus area for pharmacompanies, with billions of dollars in sales generated annually. In this blog, we take a closer look at the top 10 heart and vascular medications based on recent sales data. Eliquis (Apixaban) Eliquis 2023 sales :$12.21
The future of lifesciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, according to new research from Gartner. One of these companies is Omnipresence. I don’t think it’s possible to go back from this.
Eversana’s suite of commercialisation tools for pharmacompanies will soon have a new component – cognitive behavioural training tools designed to improve the performance of sales representatives. The post Eversana aims athletes’ mental coaching at pharmasales reps appeared first on.
In an April survey conducted by Reuters and Omnipresence, 1,363 senior professionals mostly working in pharma (82.8%) in the EMEA region (73%) and biotech, medtech/device or consumer health companies reported on how lifesciences organisations were adapting to the ‘new normal’.
Family businesses across industries including the lifesciences sector contribute significantly to the global economy – they represent about half of the world gross domestic product and global employment. In the lifesciences sector, the overall goal is to develop and commercialise innovative pharmaceutical solutions to improve health.
ODAIA, a lifesciences predictive analytics and commercial insights provider, has secured an investment of $25m in its Series B funding round. This software-as-a-service (SaaS) platform is also used by lifescience brands to launch their drugs, therapeutics and vaccines in the markets, using data-driven solution.
Pharmacompanies have improved how they engage with healthcare providers as a result of COVID-19, according to a new survey of HCPs. This has resulted in pharmacompanies being more relevant and providing more value in closing the care gap, the report says. The impact on launch.
Most small biotech companies rely on venture capitalist funding to develop new drugs but is that a good way to go? VCs invest money in biotech because they see a potential windfall via a profitable acquisition or sale, but when the FDA weighs in with delays, VCs can be ruthless. not necessarily. Only about $2.2
Pharmasales reps are rewarded in a very indirect way. That has always been difficult to measure, especially outside the US where no HCP level (only brick) prescription data is available and despite this the sales force has been by far the biggest (and most expensive) channel. About Exeevo. appeared first on.
Full lifecycle recruitment can help lifescience and pharmacompanies find the best talent to fill job postings. Recruiters, HR leaders and leaders in the lifesciences and pharma who manage people can benefit from using full lifecycle recruiting to enhance a lifesciences organization’s hiring process.
Before the Covid-19 pandemic, government-led investment and engagement in lifesciences was relatively restricted worldwide, with the industry mostly funded via private investment. The post Governments and pharma relationships and implications for antimicrobial resistance appeared first on Pharmaceutical Technology.
In 2023, there were significant advancements and notable trends in the lifesciences. Xtalks compiled a list of its top lifescience news and trends of 2023, which provided readers with the latest developments, information and expert insights across lifescience industries, including pharma, biotech and medical device.
A new survey highlights the importance of customer reference data to digital transformation and analyses ways pharmacompanies can improve the quality of their datasets. More pharmacompanies are moving in this direction, and 78% of respondents said they are undertaking, or planning, a customer data enhancement initiative.
Virtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever for pharmacompanies to maintain up-to-date customer data. Rather than simply surviving, the lifesciences industry needs to respond proactively. Make it easy for the sales team.
The lifesciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the lifesciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.
From Bristol-Myers Squibbs monumental acquisition of Celgene to Pfizers recent purchase of Seagen, these deals illustrate the strategies and ambitions driving innovation in lifesciences. While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4
Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. Market pressures. Achieving digital excellence.
The top ten pharmacompanies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharmacompanies in 2024 based on 2023 revenue.
Pharmacompany merger and acquisition (M&A) activity in the first half of 2023 has remained relatively low, consistent with the second half of last year, but investors predict deals will increase later in 2023. Experts at PWC, Goldman Sachs, and Morgan Stanley agree that pharma-related M&A is expected to pick up in 2023.
The large-sized pharma has 4,462 US-based employees. billion in first-year sales in 2011 only to be outpaced by a competitor two years later the company pivoted to cystic fibrosis. The companys flagship eye drug, Eylea (aflibercept), saw a 2% increase in US net sales in the fourth quarter of 2024, amounting to $1.50
These challenges and efficiencies need to be met head-on as companies cannot afford to allow precious customer data, with influence across marketing, sales, and service, to lay unseen gathering cobwebs. vice president lifescience and practice lead at IQVIA, experts in lifescience analytics and precision marketing.
Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. November saw the launch of a new private equity team in lifesciences at J.P. Morgan Asset Management, dubbed LifeSciences Private Capital. New CEO joins UBC.
Data is transforming lifesciences, but many organisations are not using its full potential. Lifesciences and the pharmaceutical industry are awash with data. The combination of health and data, he passionately believes, will transform lifesciences. And he has a unique view of how data and health combine.
This gives them huge amounts of customer data that allows them to shape and personalise the way they engage with their customers, not least thanks to the direct-to-consumer sales model they often offer. As part of this, a number of big pharmacompanies are also racing to develop a safe and effective vaccine for the coronavirus.
Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from lifesciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a lifesciences future very much immersed in speciality medicine?
Since the onset of the Covid-19 pandemic, lifesciencecompanies have acted quickly to address the evolving digital needs of healthcare professionals, with mixed success (see graph 1). For the most part, lifesciencecompanies have a relatively good knowledge of what their audiences want and need from them.
86% of respondents to a recent Veeva survey of pharma and biotech professionals said they are creating a greater volume of content now, compared to six months ago. To assist executives in lifesciences with scaling marketing assets in a virtual world Veeva has published a new eBook, Powering Omnichannel Strategies with Modular Content.
If pharmacompanies are to live up to their decades-old patient-centric promises then marketing budgets need to move from brands and franchises to omnichannel customer-centric teams, according to one digital transformation leader. Pharmacompanies really need to become patient, but also healthcare professional, centric.
Pharmacompanies are producing and distributing more digital content than ever due to the pandemic, meaning the content presented needs to stand out in the crowded digital space to garner attention. Content metrics is the collection of data related to an industry or a company’s content. Read the full Veeva Systems report.
The past two years have shone a spotlight on the UK lifesciences industry. Pharmacompanies are now household names, having been thrust into the public’s consciousness after dominating the headlines through the pandemic. An industry that will forever play a greater role in our everyday lives. About the author.
Emma Hyland, VP strategy, commercial content at Veeva Systems, tells us modular content is the most significant wave of innovation hitting the content world in lifesciences, and rightly so because HCPs’ needs and expectations have changed. “There isn’t a one-size-fits-all for how the lifesciences industry creates content.
Their follow-up to penicillin, Terramycin, first marketed in 1950, was both their first proprietary drug, and the first for which the company used sales reps, their soon to be formidable force of salesmen starting with just eight members. Antibiotics marked the transition to the modern Pfizer.
Pharmaceutical sales and marketing operations have been forced to follow a steep learning curve as they adjust to operating within the rapidly evolving and hugely changed landscape caused by the pandemic. Physicians didn’t want to see sales reps that were just delivering useless messages, stated Edouard.
Experts from Healthware Group explore how companies can rebuild their approach to digital from the ground up for the benefit of patients. Digital is not just a nice-to-have for pharmacompanies – it’s a necessity for ensuring that patients have the best possible outcomes in modern healthcare systems.
No more ‘business as usual’ for pharma’s customer engagement. Lifesciencescompanies need to rethink their customer engagement paradigms in light of changing customer preferences. Pharmacompanies will need to continually rethink what works and not be afraid to experiment with solutions they’ve never tried before.
For the past year, lifesciencecompanies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic. India and China have seen the emergence of strong, local pharmacompanies. About the author. Dr Subir K.
In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, lifesciences, go head-to-head to discuss marketing within a regulated industry. Sales calls that now have to start with a phone call are supported by digital and social content straightaway.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharmacompanies in the world: AstraZeneca.
In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the lifescience industry together through first holding physical events, then soon after, hosting exclusively online events. More potential patients equal more prescriptions which equals higher sales and bigger profits.
The Dublin-based pharmacompany Jazz focuses on developing therapeutics in the neuroscience and oncology spaces. Jazz Pharma had a record year in 2021 as it brought in over $3 billion in revenue for the first time in the company’s history. The net product sales of Epidiolex were $463.6 million in 2021, or $658.3
With the increasing convergence of technology and lifesciences, search for personable candidates who can pair tech-enabled solutions to patient-centered medicine. Prioritise professional development: With a scarcity of skilled labour, now is the time for pharmacompanies to tap into their greatest assets – their people.
Experts from top lifesciencescompanies discussed strategies for more effectively engaging oncologists at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Instead, he said that “innovation for the sake of utility” can help pharmacompanies maximize the impact of their digital marketing activities.
We’ve got so many great lifescience assets in the UK, but there are still some gaps – manufacturing capacity being one of them.”. “We We had companies collaborating to develop laboratories. We had companies sourcing consumables for testing machines. A collaborative future.
The latest pharmacompany to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Outsourcing services are on of the pillars of Merck’s business, delivered via its process solutions unit, part of the group’s lifesciences division.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content